Vitiligo pp 339-342 | Cite as

Vitamin D Analogues

  • Mauro Picardo


The idea that Vitamin D analogues may be considered an option for the treatment of the vitiligo arises from the casual observation of the occurrence of cutaneous perilesional hyperpigmentation after their application on psoriatic plaques together with phototherapy [6, 14, 23, 27, 28]. Starting from this clinical evidence, several in vitro and in vivo data support the therapeutic role of calcipotriol and tacalcitol for vitiligo (Table Skin cells, including keratinocytes, melanocytes, and dermal fibroblasts possess Vitamin D receptors (VDR), the activation of which induces several genes associated with proliferation and differentiation, and with the inflammatory reaction. Exposure of human melano-cytes to Vitamin D promotes tyrosinase activity and melanogenesis, together with the up-regulation of c-Kit as well as morphological modifications, mainly increases the number and length of the dendrites. With regard to keratinocytes, Vitamin D produces differentiation, decreased proliferation, and the release of the proinflammatory cytokines IL-8 and IL-6, and increased production of IL-10. In vitiligo skin, both melanocytes and keratinocytes have been shown to possess an alteration of the Ca++ uptake and a decreased intracellular concentration of the ion, which could compromise the melanogenesis by increasing the level of reduced thi-oredoxin, which inhibits tyrosinase [6].


Dermal Fibroblast Psoriatic Plaque Betamethasone Dipropionate Early Pigmentation Topical Calcipotriol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ada S, Sahin S, Boztepe G et al (2005) No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photo-immunol Photomed 21:79–83CrossRefGoogle Scholar
  2. 2.
    Amano H, Abe M, Ishikawa O (2008) First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 25:262–264PubMedCrossRefGoogle Scholar
  3. 3.
    Ameen M, Exarchou V, Chu AC (2001) Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 145:476–479PubMedCrossRefGoogle Scholar
  4. 4.
    Arca E, Tastan HB, Erbil AH et al (2006) Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 33:338–343PubMedCrossRefGoogle Scholar
  5. 5.
    Baysal V, Vildirim M, Erel A, Kesici D (2003) Is the combination of calcipotriol and PUVA effective in vitiligo? JEADV 17:299–302PubMedGoogle Scholar
  6. 6.
    Birlea SA, Costin GE, Norris DA (2008) Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 9:345–359PubMedCrossRefGoogle Scholar
  7. 7.
    Cherif F, Azaiz MI, Ben Hamida A et al (2003) Calcipotriol and PUVA as treatment for vitiligo. Dermatol Ondine J 9:4Google Scholar
  8. 8.
    Chiaverini C, Passeron T, Ortonne JP (2002) Treatment of vitiligo by topical calcipotriol. JEADV 16:137–138PubMedGoogle Scholar
  9. 9.
    Ermis O, Alpsoy E, Cetin L, Yilmaz E (2001) Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 145:472–475PubMedCrossRefGoogle Scholar
  10. 10.
    Gargoom AM, Duweb GA, Elzorghany AH et al (2004) Calcipotriol in the treatment of childood vitiligo. Int J Clin Pharmacol Res 24:11–14PubMedGoogle Scholar
  11. 11.
    Gawkrodger DJ, Ormerod AD, Shaw L et al (2008) Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159:1051–1076PubMedCrossRefGoogle Scholar
  12. 12.
    Goldinger SM, Dummer R, Schmid P et al (2007) Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. JEADV 21:504–508PubMedGoogle Scholar
  13. 13.
    Goktas EO, Aydin F, Senturk N et al (2006) Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. JEADV 20:553–557PubMedGoogle Scholar
  14. 14.
    Guilhou JJ (1998) The therapeutic effects of vitamin D3 and its analogues in psoriasis. Exp Opin Invest Drugs 7:77–84CrossRefGoogle Scholar
  15. 15.
    Hartmann A, Lurz C, Hamm H et al (2005) Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 44:736–742PubMedCrossRefGoogle Scholar
  16. 16.
    Katayama I, Ashida M, Maeda A et al (2003) Open trial of topical tacalcitol [1alpha24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of cKit mRNA by cultured melanocytes. Eur J Dermatol 13:372–376PubMedGoogle Scholar
  17. 17.
    Kullavanijaya P, Lim HW (2004) Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photoderm Photoimmunol Photomed 20:248–251CrossRefGoogle Scholar
  18. 18.
    Kumaran MS, Kaur I, Kumar B (2006) Effect of topical cal-cipotriol, betamethasone dipropionate and their combinat-tion in the treatment of localized vitiligo. JEADV 20:269–273PubMedGoogle Scholar
  19. 19.
    Leone G, Pacifico A (2005) Profile of clinical efficacy and safety of topical tacalcitol. Acta Biomed 76:13–19PubMedGoogle Scholar
  20. 20.
    Leone G, Pacifico A, Iacovelli P et al (2006) Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 31:200–205PubMedCrossRefGoogle Scholar
  21. 21.
    Lotti T, Buggiani G, Troiano M et al (2008) Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther 21(1):s20–s26PubMedCrossRefGoogle Scholar
  22. 22.
    Lu-yan T, Wen-wen F, Lei-hong X et al (2006) Topical tacal-citol and 308-nm monochromatic excimer light: a synergis-tic combination for the treatment of vitiligo. Photoderm Photoimmunol Photomed 22:310–314CrossRefGoogle Scholar
  23. 23.
    Ortonne JP, Kaufmann R, Lecha M, Goodfield M (2004) Efficacy of treatment with calcipotriol/betamethasone dipro-pionate followed by calcipotriol alone compared with tacal-citol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 209:308–313PubMedCrossRefGoogle Scholar
  24. 24.
    Parsad D, Saini R, Nagpal R (1999) Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 16:317–320PubMedCrossRefGoogle Scholar
  25. 25.
    Rodriguez-Martìn M, Garcia Bustinduy M, Saez rodriguez M, Noda Cabrera A (2009) Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 160:409–414PubMedCrossRefGoogle Scholar
  26. 26.
    Travis LB, Silverberg NB (2004) Calcipotriene and corticos-teroids combination therapy for vitiligo. Pediatr Dermatol 21:495–498PubMedCrossRefGoogle Scholar
  27. 27.
    Takahashi H, Ibe M, Kinouchi M et al (2003) Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 31:21–28PubMedCrossRefGoogle Scholar
  28. 28.
    Watabe H, Soma Y, Kawa Y et al (2002) Differentiation of murine melanocyte precursore induced by 1,25 dihy-droxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 119:583–589PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Mauro Picardo

    There are no affiliations available

    Personalised recommendations